Drugs / 68Ga-ICAM-1pep
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04596670 | Sep 2024 → Dec 2025 overdue | cancer | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-ICAM-1pep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04596670 ↗ |
| Modality | Diagnostic / imaging agent | “the ICAM-1-targeting radiotracer 68Ga-ICAM-1pep could be used for PET imaging of tumor responses to radiotherapy in cancer patients.” NCT04596670 ↗ |
| Route | Intravenous | “injected intravenously” NCT04596670 ↗ |
| Target | ICAM1 | “the ICAM-1-targeting radiotracer 68Ga-ICAM-1pep” NCT04596670 ↗ |